KP-10614

• Description:

  KP-10614 is a potent, orally active platelet aggregation inhibitor. KP-10614 inhibits platelet aggregation induced by ADP with IC50 of 1 nM. KP-10614 causes dose-dependent inhibition of ex vivo platelet aggregation in rats. KP-10614 shows antithrombotic effects in various thrombosis models. KP-10614 can be used for thrombotic diseases research[1].

• UNSPSC:

  12352211

• Target:

  Others

• Related Pathways:

  Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Smiles:

  CCC#CC[C@H] (C) [C@H] (O) /C=C/[C@@H]1[C@]2 ([H]) [C@@] (C[C@H]1O) ([H]) C=C (C2) /C=C\CCC (O) =O

• Molecular Formula:

  C23H32O4

• Molecular Weight:

  372.50

• References & Citations:

  [1]Kanayama T, et al. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog. J Pharmacol Exp Ther. 1990 Dec;255 (3) :1210-7.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  130273-99-3